Molecular Formula | C21H25N5O8S2 |
Molar Mass | 539.58 |
Melting Point | 259-261°C |
Boling Point | 637.2°C at 760 mmHg |
Flash Point | 339.1°C |
Solubility | Soluble in DMSO (>10 mg/ml), water (25 mg/ml) Note: Phosphate-containing buffers may cau |
Vapor Presure | 3.9E-16mmHg at 25°C |
Appearance | powder |
Color | white to beige |
Merck | 14,6350 |
Storage Condition | Sealed in dry,Room Temperature |
Stability | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at 4°C for up to 1 month, or at -80°C for up to 6 months. |
MDL | MFCD00941430 |
Physical and Chemical Properties | White crystalline melting point |
Use | A highly effective tryptase inhibitor. |
In vitro study | Nafamostat mesylate significantly inhibited the release of platelet beta-thromboglobulin (at 60 and 120 minutes. Nafamostat mesylate (NM) significantly prevented the release of any neutrophil elastase; At 120 min, the plasma proteinase-α1-antitrypsin complex in the NM group was 0.16 mg/mL, in the control group was 1.24 mg/ml. Nafamostat mesylate completely inhibits the formation of complexes of C1 inhibitors with kallikrein and FXIIa mesylate. Nafamostat mesylate inhibits several proteases and may be involved in the pathophysiology of disseminated intravascular coagulation (DIC). Nafamostat mesylate inhibited the activity of the extrinsic pathway (TF-F.VIIa-Xa factor production) in a concentration-dependent manner with an IC 50 of 0.1 μm. Nafamostat mesylate concentration-dependently inhibits the initial phase transient component of the biphasic ASIC3 current with an IC 50 value of about 2.5 mM. |
In vivo study | Nafamostat mesylate (10 mg/kg) inhibited trypsin-induced scratching, whereas it had no effect on histamine-and serotonin-induced scratching. Nafamostat mesylate (1-10 mg/kg) produced a dose-dependent inhibition of intradermal Compound 48/80(10 mg/site induced scratch). In mouse skin, Nafamostat methanesulfonic acid (10 mg/kg) inhibits tryptase activity. Nafamostat mesylate inhibits gemcitabine-induced NF-κB activation, potentiates gemcitabine-induced apoptosis and inhibits pancreatic tumor growth. The combination of Nafamostat mesylate and Gemicitabine ameliorates Gemicitabine-induced weight loss in mice. |
UN IDs | 3077 |
WGK Germany | nwg |
RTECS | DG2736000 |
HS Code | 29252900 |